Shares of MEDNAX Inc (NYSE:MD) have received an average recommendation of “Hold” from the thirteen analysts that are presently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $39.60.

Several equities analysts recently issued reports on the company. Zacks Investment Research cut MEDNAX from a “hold” rating to a “sell” rating in a research report on Monday, April 22nd. Citigroup set a $36.00 target price on MEDNAX and gave the stock a “buy” rating in a research report on Friday, May 3rd. Finally, Jefferies Financial Group dropped their target price on MEDNAX from $37.00 to $31.00 and set a “hold” rating on the stock in a research report on Thursday, April 11th.

MD stock traded up $0.03 during trading on Monday, hitting $25.73. The company had a trading volume of 17,229 shares, compared to its average volume of 831,485. The stock has a market capitalization of $2.22 billion, a PE ratio of 7.33, a price-to-earnings-growth ratio of 0.99 and a beta of 0.66. MEDNAX has a 1-year low of $24.30 and a 1-year high of $48.77. The company has a quick ratio of 2.55, a current ratio of 2.55 and a debt-to-equity ratio of 0.79.

MEDNAX (NYSE:MD) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $0.58 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.63 by ($0.05). The company had revenue of $851.20 million during the quarter, compared to analyst estimates of $906.35 million. MEDNAX had a negative net margin of 1.05% and a positive return on equity of 9.82%. The business’s revenue was down .2% on a year-over-year basis. During the same quarter last year, the firm earned $0.89 EPS. Analysts expect that MEDNAX will post 3.1 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MD. Quadrant Capital Group LLC boosted its stake in shares of MEDNAX by 538.6% during the 1st quarter. Quadrant Capital Group LLC now owns 1,009 shares of the company’s stock worth $26,000 after acquiring an additional 851 shares in the last quarter. Bremer Bank National Association purchased a new stake in shares of MEDNAX during the 1st quarter worth approximately $30,000. Oregon Public Employees Retirement Fund boosted its stake in shares of MEDNAX by 3,200.0% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,223,145 shares of the company’s stock worth $37,000 after acquiring an additional 1,186,080 shares in the last quarter. Tompkins Financial Corp boosted its stake in shares of MEDNAX by 352.8% during the 1st quarter. Tompkins Financial Corp now owns 806 shares of the company’s stock worth $38,000 after acquiring an additional 628 shares in the last quarter. Finally, Investors Research Corp purchased a new stake in shares of MEDNAX during the 1st quarter worth approximately $41,000. Institutional investors own 91.17% of the company’s stock.

About MEDNAX

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

Featured Article: What is Elliott Wave theory?

Analyst Recommendations for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.